Tore Jarl Gutteberg MD, PhD (dr. med.)

tore-jarl-guttenberg

Research and Projects

1. Helse Nord TB Initiative

Particpated in the startup of project and agreed to supervise two PHD students and two master students. Moses Kumwenda is successful.

Networking became an important part of the project, lead to NORHED application attempt. This got us organized into a successful GLOBVAC Breathe application.

 

2. GLOBVAC Breathe (The Research Council of Norway)

Chronic Lung Disease in HIV-infected Children in Africa, a combined pediatric and microbiology project in Malawi, Zimbabwe, with researchers from UK, SA, and Norway – almost 40 million NOK project. This is going to be developed further.

 

3. Human papillomavirus (HPV)

Human papillomavirus (HPV) causes cervical cancer, which is the second most common cancer in women worldwide by age-standardized incidence rate (ASR). Our group has since 2011 published nine papers on the use on oncogenic mRNA HPV detection (http://www.ncbi.nlm.nih.gov/pubmed/27515759)   .

 

4. Hepatitis C virus (HCV)

HCV kills more than HIV in the western world.

We have three major projects:

  1. Tromsø population study involving 20 000 people also include the prevalence of HCV, find and treat.
  2. HCV disease development until 2050 in the population og North-Norway based on our own laboratory data and literature.
  3. Since 2014 Uppsala and Tromsø are the only ones doing baseline resistance testing like what we in Scandinavia recommend for HBV and HIV. A large multicenter is in progress.

Tromsø 2016 08 18

Tore Jarl Gutteberg